ACTRN12618001001280尚未招募1 期
A Phase I, Placebo-Controlled Dose-Ranging Food Effect and Multiple Dose Study of NPI-001 Tablets in Healthy Subjects
acuity Pharmaceuticals Pty Ltd0 个研究点目标入组 32 人开始时间: 2018年6月14日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 尚未招募
- 发起方
- 入组人数
- 32
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 Years 至 60 Years（—）
- 性别
- All
入选标准
- 未提供
排除标准
- 未提供
研究者
相似试验
已完成
1 期
Investigation of the safety, tolerability and pharmacokinetics of Cannabidiol in Healthy VolunteersACTRN12618001424291Victorian State Government24
撤回
1 期
Evaluation of the Safety, Tolerability and Pharmacokinetics of Intravenous TIMP-GLIA in Healthy Volunteers.ACTRN12618000459224Delpharm Consultants Pty Ltd48
已完成
1 期
A Phase 1, placebo and positive-controlled, dose-escalation study to determine the safety, pharmacodynamics and pharmacokinetics of a single intravenous injection ofHSK3486 in healthy subjects.AnesthesiaAnaesthesiology - AnaestheticsACTRN12614000428662Sichuan Haisco Pharmaceutical Co., Ltd.48
已完成
不适用
A phase 1, placebo-controlled, ascending-dose study to assess the safety and imaging characteristics of GE-137 Injection in healthy volunteers, and to assess its safety and imaging characteristics in subjects with high suspicion of colorectal cancerColorectal cancerNL-OMON36432GE Healthcare35
已完成
不适用
A phase I, placebo controlled, dose escalation safety andpharmacokinetic study of Topical Endoxifen in healthy male volunteers.Metabolic and Endocrine - Other endocrine disordersGynecomastiaACTRN12618000569202Atossa Genetics, Inc.24